Stock listing

Hamburg:CY9D Microbot Medical Inc. Aktie

German listing (Hamburg) of Microbot Medical Inc. · home listing NASDAQ:MBOT

Follow Microbot Medical Inc. into a list and get an email when it puts out news.

Home listing price · NASDAQ:MBOT

$0.68 USD -0.04 (-5.7%)

Close on Nov 20, 2026 · This listing has no price on 6ix; the price shown is the home listing's, NASDAQ:MBOT

Past year -60.7% · daily closes, Nov 20, 2025 – Nov 20, 2026, adjusted for splits
Day range
$0.66 – $0.75 USDNov 20, 2026
Volume
1.72M sharesNov 20, 2026
Market cap
$45.67M USDAt the close on Nov 20, 2026 · price × 67.16M shares outstanding
52-week range
$0.522 – $2.86 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
Traded on an average day
$952,589 USDMedian day 587,559 shares · last 3 months, Aug 20, 2026 – Nov 20, 2026
Microbot Medical Inc. logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:MBOT · Home$0.68 USD-0.041 (-5.7%)1,722,216$0.73$0.75$0.66$0.721Close on Nov 20, 2026

Daily closes

Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:MBOT · USD, adjusted for splits

DayCloseChange%OpenHighLowVolume
$0.68-0.041-5.7%$0.73$0.75$0.661,722,216
$0.721+0.032+4.7%$0.689$0.73$0.6751,296,549
$0.689+0.045+6.9%$0.672$0.72$0.6311,709,217
$0.644-0.334-34.2%$0.65$0.664$0.52210,182,780
$0.979-0.051-5.0%$1.04$1.05$0.951,163,780
$1.03-0.08-7.2%$1.10$1.10$1.03950,151
$1.11+0.06+5.7%$1.07$1.12$1.07881,154
$1.05-0.05-4.5%$1.10$1.11$1.031,065,306
$1.10-0.01-0.9%$1.11$1.15$1.09733,296
$1.11+0.04+3.7%$1.10$1.12$1.05817,268
$1.07-0.07-6.1%$1.15$1.16$1.031,456,967
$1.14+0.05+4.6%$1.10$1.15$1.10782,480
$1.09+0.05+4.8%$1.05$1.09$1.0251,210,908
$1.04-0.05-4.6%$1.10$1.18$1.031,082,058
$1.09-0.03-2.7%$1.11$1.11$1.041,334,951
$1.120.000.0%$1.09$1.125$1.05968,346
$1.12+0.09+8.7%$1.11$1.15$1.0611,882,401
$1.03+0.088+9.4%$0.964$1.066$0.9641,156,154
$0.942-0.032-3.3%$0.981$1.00$0.941485,326
$0.974+0.032+3.4%$0.963$0.993$0.963569,354
$0.942+0.002+0.2%$0.93$0.959$0.93298,058
$0.94-0.007-0.8%$0.98$0.98$0.94485,259
$0.948-0.005-0.6%$0.958$1.03$0.945725,289
$0.953+0.003+0.3%$0.95$0.973$0.944389,479
$0.950.000.0%$0.955$1.00$0.945803,001
$0.95-0.042-4.2%$0.98$0.99$0.931,413,635
$0.992-0.028-2.8%$1.01$1.03$0.99568,186
$1.02-0.02-1.9%$1.03$1.039$1.005384,973
$1.04-0.03-2.8%$1.07$1.08$1.03423,584
$1.070.000.0%$1.08$1.085$1.05637,699
$1.07-0.05-4.5%$1.12$1.15$1.06564,616
$1.12+0.05+4.7%$1.08$1.16$1.07649,759
$1.070.000.0%$1.09$1.165$1.051,993,348
$1.07-0.09-7.8%$1.15$1.16$1.051,910,284
$1.16-0.04-3.3%$1.23$1.23$1.14852,404
$1.200.000.0%$1.21$1.23$1.18685,514
$1.20-0.045-3.6%$1.25$1.26$1.20518,813
$1.245-0.005-0.4%$1.27$1.28$1.22631,353
$1.25-0.025-2.0%$1.27$1.28$1.24424,654
$1.275-0.035-2.7%$1.32$1.33$1.26485,330
$1.310.000.0%$1.30$1.32$1.29310,503
$1.31-0.07-5.1%$1.39$1.39$1.31461,006
$1.38+0.03+2.2%$1.35$1.39$1.281,331,794
$1.35-0.01-0.7%$1.36$1.39$1.34572,436
$1.36-0.06-4.2%$1.42$1.43$1.35694,905
$1.42-0.02-1.4%$1.45$1.47$1.42388,464
$1.440.000.0%$1.44$1.48$1.43289,588
$1.44-0.01-0.7%$1.45$1.47$1.43345,779
$1.450.000.0%$1.43$1.495$1.42406,121
$1.45-0.01-0.7%$1.49$1.49$1.44446,978
$1.460.000.0%$1.45$1.475$1.45203,023
$1.46-0.04-2.7%$1.49$1.50$1.45293,567
$1.50+0.06+4.2%$1.46$1.515$1.45560,220
$1.440.000.0%$1.48$1.48$1.44406,883
$1.44-0.02-1.4%$1.48$1.489$1.44385,827
$1.46-0.01-0.7%$1.46$1.52$1.46539,798
$1.47-0.02-1.3%$1.49$1.50$1.465328,317
$1.49+0.01+0.7%$1.49$1.50$1.46404,904
$1.48-0.02-1.3%$1.50$1.51$1.46467,739
$1.50-0.02-1.3%$1.51$1.54$1.49400,396
$1.52+0.02+1.3%$1.53$1.53$1.47563,548
$1.50+0.02+1.4%$1.49$1.53$1.475587,559
$1.48-0.02-1.3%$1.50$1.57$1.471,515,036
$1.50+0.01+0.7%$1.50$1.53$1.49334,149
$1.49-0.06-3.9%$1.56$1.566$1.48613,676

Splits

4 splits since 2011 · NASDAQ:MBOT · every price before a split is adjusted for it

DayRatioWhat
1-for-15Consolidation
1-for-9Consolidation
1-for-12Consolidation
1-for-10Consolidation
Ticker
Hamburg:CY9D
Asset type
Stock
Sector
Health care
Industry
Medical devices & supplies
Exchange
Hamburg
Currency
EUR

What changed lately

Latest news

All Microbot Medical Inc. news

Microbot Medical Inc. on 6ix

Sector
Health care
Industry
Medical devices & supplies
News releases
38 in the last 12 months · 172 in all · newest Nov 16, 2026 · oldest 2019
Decks
19 decks · latest Mar 17, 2026

Where Microbot Medical Inc. is listed

ListingExchangeCountryCurrency
NASDAQ:MBOT · Home listingNASDAQUnited StatesUSD
LS Exchange:A2N5ASLS ExchangeGermanyEUR
BOATS:MBOTBOATSUnited StatesUSD
Frankfurt:CY9DFrankfurtGermanyEUR
gettex:CY9DgettexGermanyEUR
Lang & Schwarz:A2N5ASLang & SchwarzGermanyEUR
Tradegate:CY9DTradegateGermanyEUR
Dusseldorf:CY9DDusseldorfGermanyEUR
Hamburg:CY9D · This pageHamburgGermanyEUR
Munich:CY9DMunichGermanyEUR
Stuttgart:CY9DStuttgartGermanyEUR

Valuation

EV/sales −38.6× against a median of 2.9×: the lowest of 10 Medical devices & supplies companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026

Enterprise value
−$16.16M USD
P/E
Loss
EV/sales
−38.6×
EV/EBITDA
No depreciation figure on 6ix yet
Price/book
0.7×
Gross margin
−400.5%
Operating margin
Revenue too small
Net margin
Revenue too small
Debt to equity
0.0×
Beta vs S&P 500
1.82

Medical devices & supplies: the 10 companies nearest in size, of 448 on 6ix with figures. Size in US dollars.

CompanyMkt capEVP/EEV/SalesEV/EBITDAP/BNet mgnDebt/EqBeta
Microbot Medical Inc. · NASDAQ:MBOTUS$45.67M−US$16.16Mn/a−38.6×n/a0.7×n/a0.0×1.82
Venus Medtech (Hangzhou), Inc. Class H · HKEX:2500US$48.32MUS$65.50Mn/a1.4×n/a0.2×−132.9%0.1×n/a
Medimaging Integrated Solution Inc. · TWSE:6796US$48.03MUS$43.05M111×2.1×28.6×1.9×2.1%0.5×n/a
Conexeu Sciences Inc. · NASDAQ:CNXUUS$47.79MUS$45.82Mn/an/an/a8.2×n/a0.0×2.08
RenovoRx, Inc. · NASDAQ:RNXTUS$45.45MUS$35.27Mn/a12.7×n/a4.9×−469.0%0.0×1.71
Oncosem Onkolojik Sistemler Sanayi ve Ticaret A.S. · BIST:ONCSMUS$45.25MUS$45.28M31.7×2.9×7.5×4.5×9.0%0.1×n/a
Bactiguard Holding AB · OMXSTO:BACTI_BUS$45.14MUS$54.81M76.6×2.6×12.5×1.5×2.8%0.5×n/a
Somnomed Limited · ASX:SOMUS$45.09MUS$37.33Mn/a0.5×8.7×1.4×−2.3%0.1×n/a
Nuo Therapeutics Inc · OTC:AURXUS$44.38MUS$44.30Mn/a7.3×n/an/a−31.5%n/a0.73
Ortoma AB Class B · OMXSTO:ORT_BUS$44.27MUS$38.13Mn/a11.7×n/a2.6×−197.7%0.0×n/a
BrainCool AB · OMXSTO:BRAINUS$43.31MUS$39.09Mn/a9.8×n/a2.8×−84.7%0.0×n/a
Median of the othersUS$45.20MUS$43.67M76.6×2.9×10.6×2.6×−31.5%0.1×1.71

Forecasts

3 strong buy · 1 buy · Analysts' consensus from EODHD, read Nov 21, 2026. Not 6ix's view and not investment advice.

Price target
5.00 USD · Analysts' mean
EPS, year to Dec 2026
-0.32 · 3 analysts
Revenue, year to Dec 2026
700K · 3 analysts

Team and board

Officers

OfficerRole
Harel GadotCEO, President and Chairman
Rachel VakninChief Financial Officer
Allison RosefortVP, Marketing
Alon TamirVP, Sales, EMEA
Christina BaileyVP, Sales
Earl AdamyVP, Strategic Marketing & Business Development
Eran CohenVP, Global Integration
Naama MoavVP, Human Resources
Noa OferVP, Quality Assurance and Regulatory Affairs
Juan Diaz-CartelleChief Medical Officer
Simon SharonGM, Chief Technology Officer

Board

DirectorRole
Harel GadotCEO, President and Chairman
Aileen StockburgerDirector
David WilsonDirector
Martin J. MaddenDirector
Scott BurellDirector
Tal WenderowDirector

Events

QuarterResultsShare move
Q3 2026Nov 13, 2026 · After close−34.2%
Q2 2026Aug 11, 2026 · Before open−13.2%
Q1 2026May 12, 2026−0.9%
Q4 2025Mar 26, 2026 · After close−8.8%
Q3 2025Nov 12, 2025 · After close−6.1%
Q2 2025Aug 12, 2025 · After close−2.6%
Q1 2025May 14, 2025 · After close+8.5%
Q4 2024Mar 25, 2025 · After close−4.4%
Q3 2024Nov 13, 2024 · After close−5.0%
Q2 2024Aug 14, 2024 · After close+1.0%
All 20 quarters
QuarterResultsShare move
Q1 2024May 15, 2024 · Before open−2.1%
Q4 2023Mar 27, 2024 · After close+7.0%
Q3 2023Nov 14, 2023 · After close+2.2%
Q2 2023Aug 14, 2023 · Before open−0.5%
Q1 2023May 17, 2023 · After close−4.2%
Q4 2022Mar 31, 2023 · After close0.0%
Q3 2022Nov 14, 2022 · After close+11.8%
Q2 2022Aug 15, 2022 · After close−2.3%
Q1 2022May 16, 2022 · After close+4.2%
Q4 2021Mar 31, 2022 · After close+0.2%

Open Events

Decks

DeckKindSlidesDate
Investor Presentation (March 2026)Investor deck35 slidesMar 17, 2026
Investor Presentation (September 2025)Investor deck21 slidesSep 9, 2025
Investor Presentation (April 2025)Investor deck20 slidesApr 30, 2025
Investor Presentation (October 2024)Investor deck19 slidesOct 31, 2024
Investor Presentation (September 2024)Investor deck25 slidesSep 11, 2024
Investor Presentation (April 2024)Investor deck15 slidesApr 24, 2024
Investor Presentation (April 2022)Investor deck11 slidesApr 12, 2022
Investor Presentation (January 2022)Investor deck11 slidesJan 10, 2022
Investor Presentation (September 2021)Investor deck24 slidesSeptember 2021
Investor Presentation (March 2021)Investor deck26 slidesMarch 2021
All 19 decks
DeckKindSlidesDate
Investor Presentation (January 2021)Investor deck23 slidesJan 14, 2021
Investor Presentation (August 2020)Investor deck21 slidesAug 17, 2020
Investor Presentation (January 2020)Investor deck17 slidesJan 13, 2020
Investor Presentation (October 2018)Investor deck24 slidesOct 1, 2018
Investor Presentation (September 2018)Investor deck23 slidesSep 4, 2018
Ladenburg Thalmann 2017 Healthcare ConferenceConference33 slidesSep 26, 2017
Conference Presentation (September 2017)Conference33 slidesSep 8, 2017
Micro Cap Conference 2017Conference31 slidesApril 2017
Roth Conference (December 2016)Conference31 slidesDecember 2016

Open Decks

Financings

RaiseDate
Warrant exercise of common shares on exercise of outstanding preferred investment options
Closed: US$2.8M in the latest tranche · US$2.1 a share · Warrants at US$4.5 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Development, commercialization and regulatory work for the LIBERTY Robotic System, potential acquisitions, new applications, working capital
Oct 7, 2025
Registered direct offering of common stock with concurrent private placement of short-term series I preferred investment options
Closed: US$13M raised · US$2.13 a share · Warrants at US$2.13 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Development, commercialization and regulatory work for the LIBERTY Robotic System, new applications from its IP, working capital and general corporate purposes
Feb 11, 2025
Registered direct offering of common stock with concurrent private placement of short-term series H preferred investment options
Closed: US$8.6M raised · US$2.27 a share · Warrants at US$2.1 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Development, commercialization and regulatory activities for the LIBERTY Robotic System, new applications from its IP, working capital and general purposes
Jan 10, 2025
Registered direct offering of common stock with concurrent private placement of short-term series G preferred investment options
Closed: US$7M raised · US$1.75 a share · Warrants at US$1.75 for 24 months · H.C. Wainwright & Co.
Dealers: H.C. Wainwright & Co. (lead)
Use of proceeds: Development, commercialization and regulatory activities for the LIBERTY Robotic System, new applications from its IP, working capital and general corporate purposes
Jan 7, 2025
At-the-market programme of common stock
Tranche closed: US$4.8M raised
Jan 7, 2025

Open Financings · Read by 6ix AI from the company's releases

Financials

Annual, in USD

Income statement

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Revenue0000000000
Cost of revenue47.0K91.0K106.0K102.0K76.0K68.0K84.0K54.0K21.0K10.0K
Gross profit-47.0K-91.0K-106.0K-102.0K-76.0K-68.0K-84.0K-54.0K-21.0K-10.0K
Research and development6.28M6.63M5.72M7.74M6.15M3.40M3.05M2.52M1.10M-901.0K
Selling, general and administrative8.46M5.00M4.13M5.58M5.20M5.69M4.19M4.71M4.14M8.73M
Operating income-14.7M-11.6M-9.86M-13.3M-11.4M-9.09M-7.24M-7.24M5.27M-9.63M
Depreciation and amortization47.0K91.0K106.0K102.0K76.0K68.0K84.0K54.0K21.0K10.0K
EBITDA-14.7M-11.5M-9.75M-13.2M-11.3M-9.02M-7.16M-7.19M5.29M-9.63M
Interest expense131.3M44.0K80.0K103.0K0237.0K333.0K
Income before tax-13.1M-11.4M-10.7M-13.2M-11.3M-9.17M-7.25M-7.26M-7.59M-9.66M
Income tax182.0K-118.0M-44.0K0020.0K2.32M28.0K
Net income-13.1M-11.4M-10.7M-13.2M-11.3M-9.17M-7.25M-7.26M-7.59M-9.66M
Earnings per share, basic-0.29-0.73-1.05-1.81-1.59-1.29-1.70-2.41-2.760.40
Earnings per share, diluted-0.29-0.73-1.05-1.81-1.59-1.29-1.70-2.41-2.760.40

Balance sheet

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash and equivalents3.91M3.11M2.47M2.44M13.5M19.6M28.8M5.24M10.8M2.71M
Short-term investments74.7M2.36M3.92M5.76M2.00M5.00M2.52M27.0K505.0K
Receivables241.0K300.0K1.49M103.0K174.0K340.0K101.0K65.0K35.0K15.0K
Inventory584.0K0-42.0K-103.0K-174.0K-5.00K-2.62M73.0K0
Current assets79.8M5.82M7.92M8.81M15.9M25.3M35.9M5.83M10.9M3.31M
Property, plant and equipment93.0K80.0K146.0K221.0K244.0K251.0K228.0K259.0K90.0K53.0K
Goodwill00
Total assets81.5M6.03M8.33M9.54M16.8M26.3M37.1M6.09M11.0M3.37M
Accounts payable511.0K165.0K357.0K116.0K279.0K275.0K284.0K630.0K78.0K512.0K
Current liabilities3.42M2.46M3.79M2.07M1.98M1.34M4.83M4.76M528.0K783.0K
Long-term debt076.0K
Total debt865.0K111.0K231.0K462.0K680.0K813.0K903.0K76.0K
Total liabilities3.99M2.50M3.83M2.25M2.39M1.97M5.59M4.76M556.0K1.17M
Shareholders' equity77.6M3.53M4.50M7.29M14.4M24.3M31.5M1.33M9.99M1.70M
Shares outstanding67.2M19.4M11.7M7.89M7.11M7.11M7.19M3.01M2.01M15.8M

Cash flow

LineFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Cash from operations-13.0M-8.83M-8.53M-11.5M-9.35M-7.25M-6.45M-5.31M-4.86M-786.0K
Capital spending-60.0K-25.0K-33.0K-84.0K-69.0K-91.0K-216.0K-223.0K-58.0K-25.0K
Free cash flow-13.1M-8.85M-8.57M-11.6M-9.42M-7.34M-6.67M-5.53M-4.91M-811.0K
Cash from investing-72.4M1.54M1.97M-3.84M3.20M-2.77M-2.45M-223.0K-58.0K-25.0K
Cash from financing86.2M7.94M6.56M4.32M4.32M-3.38M36.8M-18.0K13.0M3.08M
Dividends paid00
Share buybacks-3.38K36.8M12.7M409.0K
Change in cash810.0K646.0K-2.00K-11.1M-6.15M-13.4M27.9M-5.55M8.11M2.27M

Open Financials

Filings

FilingDateTypeFiled with
8-K · Current reportNov 16, 2026Current reportSEC
10-Q · Quarterly reportNov 13, 2026Quarterly reportSEC
8-K · Current reportNov 5, 2026Current reportSEC
ARS · Annual report to shareholdersNov 3, 2026Annual reportSEC
DEFA14A · Additional proxy materialNov 3, 2026Meeting noticeSEC
DEF 14A · Proxy statementNov 3, 2026Meeting noticeSEC
8-K · Current reportOct 27, 2026Current reportSEC
8-K · Current reportOct 23, 2026Current reportSEC
8-K · Current reportOct 20, 2026Current reportSEC
8-K · Current reportOct 6, 2026Current reportSEC
Show 200 filings
FilingDateTypeFiled with
8-K · Current reportSep 28, 2026Current reportSEC
8-K · Current reportAug 11, 2026Current reportSEC
10-Q · Quarterly reportAug 11, 2026Quarterly reportSEC
8-K · Current reportAug 7, 2026Material contractSEC
8-K · Current reportJul 21, 2026Current reportSEC
8-K · Current reportJul 7, 2026Current reportSEC
8-K · Current reportJun 30, 2026Current reportSEC
8-K · Current reportJun 25, 2026Current reportSEC
8-K · Current reportJun 23, 2026Current reportSEC
8-K · Current reportJun 16, 2026Current reportSEC
8-K · Current reportJun 9, 2026Current reportSEC
8-K · Current reportJun 2, 2026Current reportSEC
8-K · Current reportMay 26, 2026Current reportSEC
8-K · Current reportMay 15, 2026Current reportSEC
8-K · Current reportMay 14, 2026Current reportSEC
10-Q · Quarterly reportMay 13, 2026Quarterly reportSEC
8-K · Current reportMay 5, 2026Current reportSEC
8-K · Current reportApr 30, 2026Current reportSEC
8-K · Current reportApr 22, 2026Current reportSEC
8-K · Current reportApr 14, 2026Current reportSEC
8-K · Current reportApr 13, 2026Current reportSEC
424B5 · ProspectusApr 10, 2026Offer documentSEC
8-K · Current reportApr 10, 2026Current reportSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
4 · Change in ownershipApr 3, 2026Insider tradeSEC
10-K · Annual reportMar 26, 2026Annual reportSEC
8-K · Current reportMar 26, 2026Current reportSEC
8-K · Current reportMar 24, 2026Current reportSEC
8-K · Current reportMar 17, 2026Current reportSEC
8-K · Current reportMar 10, 2026Current reportSEC
8-K · Current reportMar 4, 2026Current reportSEC
8-K · Current reportMar 3, 2026Current reportSEC
8-K · Current reportFeb 24, 2026Material contractSEC
8-K · Current reportFeb 24, 2026Current reportSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
4 · Change in ownershipFeb 20, 2026Insider tradeSEC
8-K · Current reportFeb 19, 2026Current reportSEC
8-K · Current reportFeb 12, 2026Current reportSEC
8-K · Current reportFeb 5, 2026Current reportSEC
SCHEDULE 13G · Big-stake noticeJan 23, 2026Big-stake noticeSEC
8-K · Current reportJan 12, 2026Current reportSEC
8-K · Current reportNov 26, 2025Current reportSEC
424B3 · ProspectusNov 19, 2025Offer documentSEC
424B3 · ProspectusNov 19, 2025Offer documentSEC
10-Q · Quarterly reportNov 12, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedNov 7, 2025Big-stake noticeSEC
8-K · Current reportNov 5, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedOct 31, 2025Big-stake noticeSEC
S-3/A · Registration statement, amendedOct 28, 2025Offer documentSEC
S-3/A · Registration statement, amendedOct 28, 2025Offer documentSEC
8-K · Current reportOct 16, 2025Current reportSEC
8-K · Current reportOct 14, 2025Current reportSEC
S-3 · Registration statementOct 14, 2025Offer documentSEC
S-3 · Registration statementOct 14, 2025Offer documentSEC
8-K · Current reportOct 7, 2025Material contractSEC
8-K · Current reportOct 3, 2025Material contractSEC
8-K · Current reportOct 1, 2025Current reportSEC
DSep 29, 2025Other filingsSEC
8-K · Current reportSep 23, 2025Current reportSEC
8-K · Current reportSep 19, 2025Management or board changeSEC
8-K · Current reportSep 16, 2025Material contractSEC
8-K · Current reportSep 9, 2025Current reportSEC
8-K · Current reportSep 8, 2025Current reportSEC
8-K · Current reportAug 27, 2025FinancingSEC
8-K · Current reportAug 25, 2025FinancingSEC
8-K · Current reportAug 20, 2025Current reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedAug 12, 2025Big-stake noticeSEC
10-Q · Quarterly reportAug 12, 2025Quarterly reportSEC
8-K · Current reportAug 5, 2025FinancingSEC
8-K · Current reportJul 30, 2025FinancingSEC
SCHEDULE 13G · Big-stake noticeJul 29, 2025Big-stake noticeSEC
S-8 · Registration statement for employee plansJul 22, 2025Offer documentSEC
8-K · Current reportJul 22, 2025Current reportSEC
8-K · Current reportJul 17, 2025FinancingSEC
8-K · Current reportJul 8, 2025Current reportSEC
8-K · Current reportJun 30, 2025Current reportSEC
8-K · Current reportJun 17, 2025FinancingSEC
8-K · Current reportJun 11, 2025Meeting outcomeSEC
8-K · Current reportJun 9, 2025Current reportSEC
8-K · Current reportJun 5, 2025Current reportSEC
10-Q · Quarterly reportMay 14, 2025Quarterly reportSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 12, 2025Big-stake noticeSEC
SCHEDULE 13G/A · Big-stake notice, amendedMay 9, 2025Big-stake noticeSEC
8-K · Current reportApr 30, 2025Current reportSEC
DEF 14A · Proxy statementApr 29, 2025Meeting noticeSEC
ARS · Annual report to shareholdersApr 29, 2025Annual reportSEC
DEFA14A · Additional proxy materialApr 29, 2025Meeting noticeSEC
8-K · Current reportApr 23, 2025FinancingSEC
PRE 14A · Preliminary proxy statementApr 18, 2025Meeting noticeSEC
8-K · Current reportApr 17, 2025Current reportSEC
8-K · Current reportApr 15, 2025Current reportSEC
8-K · Current reportApr 9, 2025Current reportSEC
424B3 · ProspectusApr 8, 2025Offer documentSEC
424B3 · ProspectusApr 8, 2025Offer documentSEC
424B3 · ProspectusApr 8, 2025Offer documentSEC
424B3 · ProspectusApr 8, 2025Offer documentSEC
424B3 · ProspectusApr 3, 2025Offer documentSEC
EFFECT · Notice that a registration is effectiveApr 3, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 3, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 3, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 3, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveApr 2, 2025Other filingsSEC
8-K · Current reportApr 1, 2025Current reportSEC
POS AM · Amendment to an effective registrationMar 31, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 31, 2025Offer documentSEC
CORRESP · Letter to the SECMar 28, 2025Other filingsSEC
POS AM · Amendment to an effective registrationMar 28, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 27, 2025Offer documentSEC
POS AM · Amendment to an effective registrationMar 27, 2025Offer documentSEC
S-3/A · Registration statement, amendedMar 27, 2025Offer documentSEC
10-K · Annual reportMar 25, 2025Annual reportSEC
UPLOAD · Letter from the SECMar 17, 2025Other filingsSEC
S-3 · Registration statementMar 10, 2025Offer documentSEC
8-K · Current reportMar 4, 2025Current reportSEC
DEFA14A · Additional proxy materialFeb 28, 2025Meeting noticeSEC
DEF 14A · Proxy statementFeb 28, 2025Meeting noticeSEC
8-K · Current reportFeb 25, 2025Current reportSEC
424B3 · ProspectusFeb 21, 2025Offer documentSEC
PRE 14A · Preliminary proxy statementFeb 18, 2025Meeting noticeSEC
DFeb 18, 2025Other filingsSEC
EFFECT · Notice that a registration is effectiveFeb 14, 2025Other filingsSEC
424B3 · ProspectusFeb 12, 2025Offer documentSEC
424B3 · ProspectusFeb 12, 2025Offer documentSEC
8-K · Current reportFeb 11, 2025Current reportSEC
CORRESP · Letter to the SECFeb 11, 2025Other filingsSEC
8-K · Current reportFeb 11, 2025Material contractSEC
424B5 · ProspectusFeb 11, 2025Offer documentSEC
S-1/A · Registration statement, amendedFeb 10, 2025Offer documentSEC
424B3 · ProspectusFeb 10, 2025Offer documentSEC
424B3 · ProspectusFeb 10, 2025Offer documentSEC
424B3 · ProspectusFeb 10, 2025Offer documentSEC
424B3 · ProspectusFeb 10, 2025Offer documentSEC
8-K · Current reportFeb 10, 2025Current reportSEC
UPLOAD · Letter from the SECFeb 7, 2025Other filingsSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
4 · Change in ownershipFeb 7, 2025Insider tradeSEC
8-K · Current reportFeb 7, 2025Material contractSEC
S-1 · Registration statementFeb 4, 2025Offer documentSEC
8-K · Current reportFeb 4, 2025Current reportSEC
424B3 · ProspectusFeb 3, 2025Offer documentSEC
424B3 · ProspectusFeb 3, 2025Offer documentSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
4 · Change in ownershipJan 30, 2025Insider tradeSEC
8-K · Current reportJan 27, 2025Current reportSEC
8-K · Current reportJan 24, 2025Management or board changeSEC
DJan 22, 2025Other filingsSEC
DJan 22, 2025Other filingsSEC
8-K · Current reportJan 21, 2025Current reportSEC
3 · Initial statement of ownershipJan 16, 2025Insider tradeSEC
SCHEDULE 13G · Big-stake noticeJan 13, 2025Big-stake noticeSEC
SCHEDULE 13G · Big-stake noticeJan 10, 2025Big-stake noticeSEC
8-K · Current reportJan 10, 2025Material contractSEC
424B5 · ProspectusJan 10, 2025Offer documentSEC
8-K · Current reportJan 7, 2025Material contractSEC
424B5 · ProspectusJan 7, 2025Offer documentSEC
424B3 · ProspectusJan 6, 2025Offer documentSEC
424B3 · ProspectusJan 6, 2025Offer documentSEC
8-K · Current reportJan 6, 2025Current reportSEC
8-K · Current reportDec 30, 2024Current reportSEC
8-K · Current reportDec 19, 2024Management or board changeSEC
424B3 · ProspectusDec 10, 2024Offer documentSEC
424B3 · ProspectusDec 10, 2024Offer documentSEC
8-K · Current reportDec 10, 2024Current reportSEC
10-Q · Quarterly reportNov 13, 2024Quarterly reportSEC
DEFA14A · Additional proxy materialNov 6, 2024Meeting noticeSEC
ARS · Annual report to shareholdersNov 6, 2024Annual reportSEC
DEF 14A · Proxy statementNov 6, 2024Meeting noticeSEC
8-K · Current reportOct 31, 2024Current reportSEC
424B3 · ProspectusOct 15, 2024Offer documentSEC
424B3 · ProspectusOct 15, 2024Offer documentSEC
8-K · Current reportOct 15, 2024Current reportSEC
8-K · Current reportOct 11, 2024Current reportSEC
424B3 · ProspectusOct 1, 2024Offer documentSEC
424B3 · ProspectusOct 1, 2024Offer documentSEC
8-K · Current reportSep 30, 2024Current reportSEC
8-K · Current reportSep 17, 2024Current reportSEC
8-K · Current reportSep 11, 2024Current reportSEC
424B3 · ProspectusAug 22, 2024Offer documentSEC

This page holds 200 of 1,001 filings. Open Filings

Open Filings · All of its filings on SEC EDGAR

Cap table

Built by 6ix from Microbot Medical Inc.’s releases · as of Nov 12, 2026

Common shares
67,164,801
Fully diluted
67,164,801

Fully diluted

LineSharesAs of
Common shares67,164,801Nov 12, 2026

Warrants and options

Lot
Warrants · US$4.50 · expire about Oct 2027
Warrants · US$2.13 · expire about Feb 2027
Warrants · US$2.10 · expire about Jan 2027
Warrants · US$1.75 · expire about Jan 2027

Share count over time

CountShares
Nov 12, 202667,164,801

Open Cap table

Shareholders

Institutions

HolderSharesOf the companyValueAs of
Vanguard3.34M5.0%US$4.01MSep 30, 2026
MUFG1.33M2.0%US$1.6MSep 30, 2026
BlackRock892K1.3%US$1.07MSep 30, 2026
UBS843K1.3%US$1.01MSep 30, 2026
Geode Capital780K1.2%US$937KSep 30, 2026
Dnb Asset Management As677K1.0%US$813KSep 30, 2026
Stifel Financial Corp559K0.83%US$671KSep 30, 2026
Susquehanna539K0.80%US$647KSep 30, 2026
Marshall Wace, LLP417K0.62%US$500KSep 30, 2026
Citadel364K0.54%US$437KSep 30, 2026
Show 50 holders
HolderSharesOf the companyValueAs of
State Street304K0.45%US$364KSep 30, 2026
AlphaCentric Advisors LLC250K0.37%US$300KSep 30, 2026
Hrt Financial LP163K0.24%US$195KSep 30, 2026
Virtu Financial LLC162K0.24%US$195KSep 30, 2026
Northern Trust148K0.22%US$177KSep 30, 2026
Invesco80,5260.12%US$96,631Sep 30, 2026
Vontobel Holding Ltd.75,6630.11%US$90,796Sep 30, 2026
Group One Trading LLC63,7640.09%US$76,517Sep 30, 2026
Quadrature Capital Ltd63,6820.09%US$76,418Sep 30, 2026
BNY49,4540.07%US$59,344Sep 30, 2026
XTX Topco Ltd48,0560.07%US$57,667Sep 30, 2026
Integrity Alliance, LLC.46,5350.07%US$55,842Sep 30, 2026
Jane Street43,2320.06%US$51,879Sep 30, 2026
Lazari Capital Management, Inc.41,9000.06%US$50,280Sep 30, 2026
Cetera Investment Advisers41,3110.06%US$49,573Sep 30, 2026
Simplex Trading, LLC38,2420.06%US$45,890Sep 30, 2026
Hilltop Holdings Inc.36,4640.05%US$43,757Sep 30, 2026
Scotiabank32,8760.05%US$39,451Sep 30, 2026
Beacon Capital Management, LLC32,0000.05%US$38,400Sep 30, 2026
LPL Financial LLC29,7930.04%US$35,752Sep 30, 2026
Squarepoint Ops LLC21,1530.03%US$25,384Sep 30, 2026
Blair William & Co20,1820.03%US$24,218Sep 30, 2026
Citigroup Inc16,9250.03%US$20,310Sep 30, 2026
Osaic Holdings, Inc.16,6050.02%US$19,925Sep 30, 2026
Two Sigma13,9450.02%US$16,734Sep 30, 2026
Focus Partners Wealth13,5680.02%US$16,282Sep 30, 2026
Private Advisor Group, LLC12,5390.02%US$15,047Sep 30, 2026
Morgan Stanley11,3520.02%US$13,622Sep 30, 2026
Cerity Partners LLC10,6450.02%US$12,774Sep 30, 2026
Cornerstone Advisory, LLC10,0000.01%US$12,000Sep 30, 2026
OpenArc Corporate Advisory, LLC10,0000.01%US$12,000Sep 30, 2026
Wells Fargo8,7340.01%US$10,481Sep 30, 2026
Tower Research Capital LLC (TRC)6,414<0.01%US$7,697Sep 30, 2026
Bfsg, LLC5,500<0.01%US$6,600Sep 30, 2026
SBI Securities Co., Ltd.3,412<0.01%US$4,094Sep 30, 2026
Nuveen3,052<0.01%US$3,800Sep 30, 2026
Fidelity2,883<0.01%US$3,459Sep 30, 2026
Steward Partners Investment Advisory, LLC2,300<0.01%US$2,760Sep 30, 2026
Avion Wealth2,000<0.01%US$2,000Sep 30, 2026
Guardian Partners Inc.2,000<0.01%US$2,400Sep 30, 2026

This page holds 50 of 72 holders. Open Shareholders

Funds

HolderSharesOf the companyValueAs of
Vanguard Total Stock Market Index Fund2.11M3.1%US$4.11MJun 30, 2026
Vanguard Extended Market Index Fund740K1.1%US$1.44MJun 30, 2026
Fidelity Extended Market Index Fund354K0.53%US$719KMay 31, 2026
AlphaCentric Robotics and Automation Fund250K0.37%US$488KJun 30, 2026
iShares Micro-Cap ETF231K0.34%US$450KJun 30, 2026
Fidelity Total Market Index Fund117K0.17%US$237KMay 31, 2026
Fidelity Series Total Market Index Fund102K0.15%US$206KMay 31, 2026
Avantis U.S. Small Cap Equity ETF93,3140.14%US$189KMay 31, 2026
Schwab Total Stock Market Index Fund50,0000.07%US$86,000Jul 31, 2026
Ultra-Small Company Fund44,3000.07%US$86,385Jun 30, 2026
All 23 holders
HolderSharesOf the companyValueAs of
Fidelity Nasdaq Composite Index Fund36,4010.05%US$73,894May 31, 2026
Fidelity ZERO Total Market Index Fund34,5640.05%US$59,450Jul 31, 2026
Vanguard Balanced Index Fund32,4140.05%US$63,207Jun 30, 2026
Invesco NASDAQ Future Gen 200 ETF31,8840.05%US$64,725May 31, 2026
Vanguard Institutional Total Stock Market Index Fund24,6910.04%US$48,147Jun 30, 2026
Fidelity ZERO Extended Market Index Fund23,4340.03%US$40,306Jul 31, 2026
1290 VT Micro Cap Portfolio15,5910.02%US$30,402Jun 30, 2026
Fidelity Flex Small Cap Index Fund11,8510.02%US$20,384Jul 31, 2026
Victory Extended Market Index Fund7,0540.01%US$12,133Jul 31, 2026
VIP Extended Market Index Portfolio4,854<0.01%US$9,465Jun 30, 2026
VIP Total Market Index Portfolio1,655<0.01%US$3,227Jun 30, 2026
Total Stock Market Index Trust1,280<0.01%US$2,496Jun 30, 2026
State Street Balanced Index Fund904<0.01%US$1,763Jun 30, 2026

Big stakes

StakeStakeSharesDateFiling
Mitchell P. Kopin8.20%6MJan 15, 2026Schedule 13G

Open Shareholders

People

6ix reads each seat by machine from the page it links to, and can misread one.

PersonSeat
Gregory T Schiffman
Other companies: Fabric.AI, Inc. (Director · Since at least Jan 30, 2018); Nanomix Corporation (Director · Mar 2, 2022 – Dec 21, 2022 · Past); Absci Corporation (Chief Financial Officer · Jul 21, 2021 – Mar 1, 2023 · Past); Iovance Biotherapeutics, Inc. (Chief Financial Officer · Oct 3, 2016 – Nov 14, 2016 · Past); Dendreon Corp (EVP · Dec 18, 2006 – Oct 20, 2013 · Past); Xenogen Corp (Director · Aug 9, 2006 – Aug 9, 2006 · Past); Vnus Medical Technologies Inc (Director · Apr 3, 2006 – Jun 17, 2009 · Past); Affymetrix Inc (EVP & Chief Financial Officer · Jan 5, 2006 – Aug 4, 2006 · Past)
Chief Financial Officer · Jan 1, 2014 – Mar 15, 2016 · Past
R. Scott Greer
Other companies: Nektar Therapeutics (Managing Director, Numenor Ventures, LLC · Since at least Sep 15, 2015); Inogen, Inc (Director · Aug 3, 2015 – May 10, 2021 · Past); Aravive Inc (Director · Jun 29, 2015 – Dec 20, 2017 · Past); Sientra Inc (Director · Jun 26, 2015 – Jun 5, 2018 · Past)
Director · Jan 1, 2016 – Jan 1, 2016 · Past
Scott Burell
Other companies: Expion360 Inc. (Chairman of the Board and Independent Director · Since at least Oct 16, 2025); DIH Holdings US, Inc (Director · Since at least Aug 4, 2025); AgEagle Aerial Systems, Inc. (Director · Mar 26, 2018 – May 21, 2019 · Past); CombiMatrix Corp (CFO, Secretary & Treasurer · Apr 7, 2011 – Nov 14, 2017 · Past)
Director · Since at least Nov 28, 2016
Ricardo B Levy
Other companies: Renegy Holdings Inc (Director · Oct 1, 2007 – Apr 17, 2009 · Past); Accelrys Inc (Director · Aug 4, 2006 – Mar 6, 2013 · Past)
Director · Sep 26, 2006 – Jan 1, 2016 · Past
Desmond H Oconnell Jr
Other companies: Serologicals Corp (Director · Jan 12, 2006 – Jul 14, 2006 · Past)
Director · Jan 10, 2007 – Mar 7, 2007 · Past
Harel Gadot
Other companies: Brenmiller Energy Ltd (Director · Since at least Mar 18, 2026)
CEO, President and Chairman · Since at least Dec 23, 2019
Irving Weissman
Other companies: Forty Seven Inc (Director · Jun 27, 2018 – Apr 7, 2020 · Past)
Director · Oct 1, 2006 – Apr 1, 2016 · Past
Martin J. Madden
Other companies: NovoCure Limited (Director · Since at least May 21, 2019)
Director · Since at least Oct 23, 2019
Yoseph Bornstein
Other companies: Can-Fite BioPharma Ltd. (Director · Since at least Mar 18, 2026)
Director · Nov 28, 2016 – Nov 2, 2023 · Past
Aileen StockburgerDirector · Since at least Apr 1, 2020
All 32 people
PersonSeat
Alan O TrounsonDirector · Jul 7, 2014 – Jan 1, 2016 · Past
Allison RosefortVP, Marketing · Since at least Apr 23, 2025
Alon TamirVP, Sales, EMEA · Since at least May 5, 2026
Ann TsukamotoEVP, Research and Development · Mar 10, 2009 – Jan 27, 2015 · Past
Christina BaileyVP, Sales · Since at least Jun 16, 2026
David WilsonDirector · Since at least Dec 17, 2024
Earl AdamyVP, Strategic Marketing & Business Development · Since at least Mar 10, 2026
Eran CohenVP, Global Integration · Since at least Nov 4, 2026
Eyal MoragChief Medical Officer · May 1, 2020 – Aug 1, 2023 · Past
John J SchwartzDirector · Apr 18, 2006 – Jan 1, 2016 · Past
Juan Diaz-CartelleChief Medical Officer · Since at least Dec 1, 2023
Kenneth Blair StrattonGeneral Counsel · May 15, 2013 – Jun 17, 2016 · Past
Martin M McGlynnPresident & CEO, Director · Mar 31, 2006 – Jan 8, 2016 · Past
Mayer SolomonDirector · Nov 28, 2016 – Nov 28, 2016 · Past
Moshe ShohamDirector · Nov 28, 2016 – Oct 5, 2017 · Past
Naama MoavVP, Human Resources · Since at least Apr 23, 2025
Noa OferVP, Quality Assurance and Regulatory Affairs · Since at least Nov 4, 2026
Prattipati LaxminarainDirector · Since at least Apr 1, 2026
Rachel VakninChief Financial Officer · Since at least Apr 1, 2022
Simon SharonGeneral Manager, CTO · Since at least Apr 7, 2021
Tal WenderowDirector · Since at least Aug 1, 2020
Yehezkel HimelfarbCOO and General Manager, Director · Dec 5, 2016 – Oct 15, 2017 · Past

Open People

Log in to ask 6ix AI your own questions about Microbot Medical Inc.